Johanna Pennlert1, Kjell Asplund2, Bo Carlberg2, Per-Gunnar Wiklund2, Aase Wisten2, Signild Åsberg2, Marie Eriksson2. 1. From the Department of Public Health and Clinical Medicine and Department of Medicine (J.P., K.A., B.C., P.-G.W.), Department of Community Medicine and Rehabilitation, Geriatric Medicine, Sunderby Research Unit (A.W.), and Department of Statistics, Umeå School of Business and Economics (M.E.), Umeå University, Sweden; and Department of Medical Sciences, Uppsala University, Sweden (S.Å.). johanna.pennlert@vll.se. 2. From the Department of Public Health and Clinical Medicine and Department of Medicine (J.P., K.A., B.C., P.-G.W.), Department of Community Medicine and Rehabilitation, Geriatric Medicine, Sunderby Research Unit (A.W.), and Department of Statistics, Umeå School of Business and Economics (M.E.), Umeå University, Sweden; and Department of Medical Sciences, Uppsala University, Sweden (S.Å.).
Abstract
BACKGROUND AND PURPOSE: Patients who survive intracerebral hemorrhage (ICH) often have compelling indications for anticoagulant and antiplatelet medication. This nationwide observational study aimed to determine the extent and predictors of antithrombotic treatment after ICH in Sweden. METHODS: Patients with a first-ever ICH in the Swedish Stroke Register (Riksstroke) 2005 to 2012 who survived hospital discharge were included. Riksstroke data were individually linked with other national registers to determine comorbid conditions and dispensed prescriptions of antithrombotic agents. RESULTS: Among the 2777 patients with atrial fibrillation (AF), the proportion with a dispensed prescription of antithrombotic agents was 8.5% (anticoagulants) and 36.6% (antiplatelet agents) within 6 months and 11.1% (anticoagulants) and 43.6% (antiplatelet agents) within 1 year. Among the 11 268 patients without AF, the corresponding figures were 1.6% (anticoagulants) and 13.8% (antiplatelet agents) within 6 months and 2.0% (anticoagulants) and 17.5% (antiplatelet agents) within 1 year. In patients with AF, predictors of anticoagulant treatment were less severe ICH, younger age, previous anticoagulation, valvular disease, and previous ischemic stroke. High CHA2DS2-VASc (congestive heart failure, hypertension, age, diabetes mellitus, stroke [doubled], vascular disease, age, and sex category [female]) scores did not correlate with anticoagulant treatment. There was a positive correlation between high CHA2DS2-VASc and HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly, drugs/alcohol) scores (rs=0.590, P<0.001). CONCLUSIONS: In majority of patients who receive antithrombotic agents, treatment is initiated within 6 months of ICH. Still, many patients with compelling indications for antithrombotic treatment are not prescribed antithrombotic agents. Factors other than high risk of embolic stroke by CHA2DS2-VASc in ICH survivors with concurrent AF are used to guide the anticoagulant treatment decision in Swedish clinical practice.
BACKGROUND AND PURPOSE:Patients who survive intracerebral hemorrhage (ICH) often have compelling indications for anticoagulant and antiplatelet medication. This nationwide observational study aimed to determine the extent and predictors of antithrombotic treatment after ICH in Sweden. METHODS:Patients with a first-ever ICH in the Swedish Stroke Register (Riksstroke) 2005 to 2012 who survived hospital discharge were included. Riksstroke data were individually linked with other national registers to determine comorbid conditions and dispensed prescriptions of antithrombotic agents. RESULTS: Among the 2777 patients with atrial fibrillation (AF), the proportion with a dispensed prescription of antithrombotic agents was 8.5% (anticoagulants) and 36.6% (antiplatelet agents) within 6 months and 11.1% (anticoagulants) and 43.6% (antiplatelet agents) within 1 year. Among the 11 268 patients without AF, the corresponding figures were 1.6% (anticoagulants) and 13.8% (antiplatelet agents) within 6 months and 2.0% (anticoagulants) and 17.5% (antiplatelet agents) within 1 year. In patients with AF, predictors of anticoagulant treatment were less severe ICH, younger age, previous anticoagulation, valvular disease, and previous ischemic stroke. High CHA2DS2-VASc (congestive heart failure, hypertension, age, diabetes mellitus, stroke [doubled], vascular disease, age, and sex category [female]) scores did not correlate with anticoagulant treatment. There was a positive correlation between high CHA2DS2-VASc and HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly, drugs/alcohol) scores (rs=0.590, P<0.001). CONCLUSIONS: In majority of patients who receive antithrombotic agents, treatment is initiated within 6 months of ICH. Still, many patients with compelling indications for antithrombotic treatment are not prescribed antithrombotic agents. Factors other than high risk of embolic stroke by CHA2DS2-VASc in ICH survivors with concurrent AF are used to guide the anticoagulant treatment decision in Swedish clinical practice.
Authors: Santosh B Murthy; Ivan Diaz; Xian Wu; Alexander E Merkler; Costantino Iadecola; Monika M Safford; Kevin N Sheth; Babak B Navi; Hooman Kamel Journal: Stroke Date: 2019-11-27 Impact factor: 7.914
Authors: Andreas Charidimou; Andrea Morotti; Raffaella Valenti; Anne-Katrin Giese; Gregoire Boulouis; Marco Pasi; Duangnapa Roongpiboonsopit; Arne Lauer; Li Xiong; Thijs Wijnzen Van Harten; Hasan Karadeli; Panagiotis Fotiadis; Michael James Jessel; Anand Viswanathan Journal: Neurology Date: 2016-05-17 Impact factor: 9.910
Authors: Jochen A Sembill; Claudia Y Wieser; Maximilian I Sprügel; Stefan T Gerner; Antje Giede-Jeppe; Caroline Reindl; Ilker Y Eyüpoglu; Philip Hoelter; Hannes Lücking; Joji B Kuramatsu; Hagen B Huttner Journal: J Neurol Date: 2018-08-20 Impact factor: 4.849
Authors: Santosh B Murthy; Ajay Gupta; Alexander E Merkler; Babak B Navi; Pitchaiah Mandava; Costantino Iadecola; Kevin N Sheth; Daniel F Hanley; Wendy C Ziai; Hooman Kamel Journal: Stroke Date: 2017-04-17 Impact factor: 7.914
Authors: Santosh B Murthy; Xian Wu; Ivan Diaz; Melvin Parasram; Neal S Parikh; Costantino Iadecola; Alexander E Merkler; Guido J Falcone; Stacy Brown; Alessandro Biffi; Judy Ch'ang; Jared Knopman; Philip E Stieg; Babak B Navi; Kevin N Sheth; Hooman Kamel Journal: Stroke Date: 2020-03-17 Impact factor: 7.914
Authors: Santosh B Murthy; Alessandro Biffi; Guido J Falcone; Lauren H Sansing; Victor Torres Lopez; Babak B Navi; David J Roh; Pitchaiah Mandava; Daniel F Hanley; Wendy C Ziai; Hooman Kamel; Jonathan Rosand; Kevin N Sheth Journal: Stroke Date: 2019-09-20 Impact factor: 10.170